Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations
Hartmut Döhner(University Hospital Ulm), Andrew H. Wei(The Royal Melbourne Hospital), Nikki Daskalakis(Johnson & Johnson (United States)), Valentina Mancini(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Kathryn Packman(Johnson & Johnson (United States)), Olga Salamero(Vall d'Hebron Institut de Recerca), Amir T. Fathi(University of Southern California), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Ulrike Philippar(Janssen (Belgium)), Jordi Esteve(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Marie Luise Hütter‐Krönke(University Hospital Ulm), Brett Hiebert(Johnson & Johnson (United States)), Jenny O’Nions(University College London Hospitals NHS Foundation Trust), Stan Gaj(Maastricht University), Marina Konopleva(Albert Einstein College of Medicine), Pierre Bories, Juan Manuel Alonso‐Domínguez(Hospital Universitario Fundación Jiménez Díaz), Jan Krönke(Universitätsmedizin Greifswald), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes), Ioannis Mantzaris(Montefiore Medical Center), James Dugan(Novant Health), Prathap Nagaraja Shastri(Springhouse), Emma Searle(University of Manchester), Sylvain Garciaz(Centre National de la Recherche Scientifique), Ana Alfonso Piérola(Istituti di Ricovero e Cura a Carattere Scientifico), Lucille Ferrante(Johnson & Johnson (United States)), Natalia Tovar(Hospital Clínic de Barcelona), Christina Loefgren(Janssen (United States)), Ibrahim Aldoss(City of Hope), Laura Barreyro(Albert Einstein College of Medicine), Christina Guttke(Johnson & Johnson (United States)), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Oliver Lomas(Johnson & Johnson (United States)), Matteo Della Porta(University of Milan), Sara Garrido Paniagua(Vall d'Hebron Institut de Recerca), Nicolas Vallet(Université de Tours), Ana Garrido(Hospital de Sant Pau), Madlen Jentzsch, Paresh Vyas(University of Oxford), Uwe Platzbecker(National Center for Tumor Diseases), Emmanuel Gyan(Inserm), Tim Sauer(Heidelberg University), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Lachlin Vaughan(Westmead Hospital), Daniel Morillo(Sheba Medical Center), Amber D'Souza(Johnson & Johnson (United States)), Alicia J. Allred(Queen's University Belfast), Naa Sackey(Johnson & Johnson (United States)), Andre C. Schuh(University of Toronto)
Cited by 10
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k